De Angeli Pietro, Flores-Tufiño Arturo, Stingl Katarina, Kühlewein Laura, Roschi Eleonora, Wissinger Bernd, Kohl Susanne
Institute for Ophthalmic Research, Centre for Ophthalmology, University Clinics Tübingen, Elfriede-Aulhorn-Str. 7, 72076 Tübingen, Germany.
University Eye Hospital, Centre for Ophthalmology, University Clinics Tübingen, Elfriede-Aulhorn-Str. 7, 72076 Tübingen, Germany.
Mol Ther Nucleic Acids. 2023 Dec 27;35(1):102113. doi: 10.1016/j.omtn.2023.102113. eCollection 2024 Mar 12.
Splicing defects from deep-intronic variants significantly contribute to the mutational spectrum in -associated inherited retinal diseases, necessitating functional validation for their pathological classification. Typically, minigene assays in HEK293(T) can qualitatively assess splicing defects, yet they often fail to quantitatively reproduce the resulting mis-splicing patterns, leaving uncertainty on severity and pathogenicity. As a potential cellular model derived from patient cells, photoreceptor precursor cells (PPCs) play a pivotal role in assessing the severity of specific splicing mutations. Nevertheless, the accessibility of biosamples is commonly constrained, and their establishment is costly and laborious. In this study, we combined and investigated the use of a minigene assay and isogenic PPCs, as superior qualitative and more accessible cellular models for the assessment of splicing defects. Specifically, we focused on the clustered c.5196+1013A>G, c.5196+1056A>G, and c.5196+1216C>A deep-intronic variants in intron 36 of , comparing their resulting (mis)splicing patterns in minigene-transfected cells and isogenic CRISPR-Cas9-knocked-in PPCs harboring these pathogenic variants in homozygous state. Moreover, we demonstrate the successful correction of these three splicing defects in homozygous mutant PPCs using a single pair of guide RNAs to target Cas9 cleavage, thereby identifying an efficient gene editing strategy for therapeutic applications.
深度内含子变异导致的剪接缺陷在相关遗传性视网膜疾病的突变谱中占显著比例,因此需要对其进行功能验证以进行病理分类。通常,在HEK293(T)细胞中进行的小基因检测可以定性评估剪接缺陷,但它们往往无法定量重现由此产生的错误剪接模式,从而在严重程度和致病性方面留下不确定性。作为一种源自患者细胞的潜在细胞模型,光感受器前体细胞(PPCs)在评估特定剪接突变的严重程度方面起着关键作用。然而,生物样本的获取通常受到限制,并且其建立成本高昂且费力。在本研究中,我们结合并研究了小基因检测和同基因PPCs的使用,作为评估剪接缺陷的更优定性和更易获取的细胞模型。具体而言,我们聚焦于基因第36内含子中的成簇c.5196+1013A>G、c.5196+1056A>G和c.5196+1216C>A深度内含子变异,比较它们在小基因转染细胞和纯合状态下携带这些致病变异的同基因CRISPR-Cas9敲入PPCs中产生的(错误)剪接模式。此外,我们展示了使用一对引导RNA靶向Cas9切割成功纠正纯合突变PPCs中的这三种剪接缺陷,从而确定了一种用于治疗应用的有效基因编辑策略。